Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness
- PMID: 15963044
- DOI: 10.1111/j.1365-3083.2005.01627.x
Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness
Abstract
Mice immunized intranasally with a formalin-inactivated A/PR/8/34 (H1N1) influenza whole virus vaccine adjuvanted with cholera toxin, outer membrane vesicles from group B meningococci or formalin-inactivated whole cell Bordetella pertussis were protected against replication of the homologous virus in the nasal cavity. Only some mice were protected against clinical illness measured as weight loss and lowered body temperature. All mice immunized subcutaneously with one-tenth the intranasal vaccine dose without adjuvant were protected against clinical illness but not against local mucosal viral replication. Replicating virus was primarily found in animals with low concentrations of immunoglobulin (Ig)-A antibodies in saliva regardless of concentrations of IgG antibodies in serum. Clinical illness was seen only in those with low serum antibodies regardless of antibody levels in saliva. Nonreplicating nasal vaccines may not be sufficiently protective unless they also have a substantial influence on systemic immunity.
Similar articles
-
Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10. Virology. 2008. PMID: 18786689
-
Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.J Immunol. 1992 Aug 1;149(3):981-8. J Immunol. 1992. PMID: 1634780
-
Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23. Vaccine. 2012. PMID: 22537989
-
Studies on the usefulness of intranasal inactivated influenza vaccines.Vaccine. 2010 Aug 31;28(38):6393-7. doi: 10.1016/j.vaccine.2010.05.019. Epub 2010 May 20. Vaccine. 2010. PMID: 20493820 Review.
-
[Nasal vaccines].Nihon Rinsho. 2008 Oct;66(10):1881-7. Nihon Rinsho. 2008. PMID: 18939485 Review. Japanese.
Cited by
-
A Fusion Protein Based on the Second Subunit of Hemagglutinin of Influenza A/H2N2 Viruses Provides Cross Immunity.Acta Naturae. 2016 Apr-Jun;8(2):116-26. Acta Naturae. 2016. PMID: 27437146 Free PMC article.
-
Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.PLoS One. 2015 Mar 23;10(3):e0119520. doi: 10.1371/journal.pone.0119520. eCollection 2015. PLoS One. 2015. PMID: 25799221 Free PMC article.
-
Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.Clin Vaccine Immunol. 2009 Apr;16(4):471-8. doi: 10.1128/CVI.00311-08. Epub 2009 Feb 4. Clin Vaccine Immunol. 2009. PMID: 19193829 Free PMC article.
-
Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.Vaccine. 2012 Nov 6;30(48):6871-7. doi: 10.1016/j.vaccine.2012.09.007. Epub 2012 Sep 16. Vaccine. 2012. PMID: 22989689 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous